Probiotic Lactobacillus reuteri has been shown to be useful for a number of gastrointestinal disorders. Its ability to secrete antimicrobial compounds, prevent pathogenic microorganisms from colonizing the host, and alter the composition of the commensal microbiota in the host are all major contributors to its therapeutic advantages. Not only that, but L. reuteri treatment strengthens the host's defenses against infection and pro-inflammatory cytokine production while enhancing the growth and functionality of regulatory T cells. Numerous pediatric illnesses, particularly those pertaining to the intestinal health of infants, have been found to be well managed by L. reuteri, according to systematic reviews and meta-analyses. According to current research on L. reuteri, it may be useful in the management and avoidance of a number of common clinical disorders, including functional constipation, infantile colic, regurgitation, and diarrhea. Probiotic treatment for pediatric illnesses has had favorable benefits on bowel regularity in individuals with chronic constipation and has been found to successfully reduce screaming and/or fussing time in newborns with colic. Additionally, it quickens the emptying of the stomach and lessens distension. Several research have even come to the conclusion that this probiotic strain reduces the frequency of regurgitation. The potential of this probiotic strain for application in the treatment of several gastrointestinal disorders is evident from all of these findings. Therefore, this study aims to encapsulate and condense the advantages of this probiotic strain in clinical settings, with a particular emphasis on how it supports babies' and toddlers' immune systems and gut health.
| Published in | International Journal of Gastroenterology (Volume 8, Issue 1) |
| DOI | 10.11648/j.ijg.20240801.14 |
| Page(s) | 14-21 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Lactobacillus reuteri, Probiotics, Gut Health, Immunomodulation, Infants, Functional Gastrointestinal Disorders, Functional Constipation, Infantile Colic
| [1] | Lee J, Yang W, Hostetler A. et al. Characterization of the anti inflammatory Lactobacillus reuteri BM36301 and its probiotic benefits on aged mice. BMC Microbiol; 2016; 16: 69. |
| [2] | Derrien M, Alvarez AS, de Vos WM. The Gut Microbiota in the First Decade of Life. Trends Microbiol. 2019; 27: 997-10. |
| [3] | Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30: 492–06. |
| [4] | Srinivasan R, Kesavelu D, Veligandla KC, et al. Lactobacillus reuteri DSM 17938: Review of evidence in functional gastrointestinal disorders. Pediatr Ther. 2018; 8: 350-57. |
| [5] | Mu Q, Tavella VJ, & Luo XM. Role of Lactobacillus reuteri in Human Health and Diseases. Front in microbio, 2018; 9: 757. |
| [6] | Collado, M. C.; Rautava, S.; Aakko, J.; Isolauri, E.; Salminen, S. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci. Rep. 2016, 6, 23129. |
| [7] | Martinez, K. A., Romano-Keeler, J.; Zackular, J. P.; Moore, D. J.; Brucker, R. M.; Hooper, C.; Meng, S.; Brown, M.; Mallal, S.; Reese, J.; et al. Bacterial DNA is present in the fetal intestine and overlaps with that in the placenta in mice. PLoS ONE 2018, 13, e0197439. |
| [8] | Bäckhed, F.; Roswall, J.; Peng, Y.; Feng, Q.; Jia, H.; Kovatcheva-Datchary, P.; Li, Y.; Xia, Y.; Xie, H.; Zhong, H.; et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell. Host Microbe 2015, 17, 690–703. |
| [9] | De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J. B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691–14696. |
| [10] | Turta, O.; Rautava, S. Antibiotics, obesity and the link to microbes—What are we doing to our children, BMC Med. 2016, 14, 57. |
| [11] | Vandenplas Y, Hauser B, Salvatore S. Functional Gastrointestinal Disorders in Infancy: Impact on the Health of the Infant and Family. Pediatr Gastroenterol Hepatol Nutr. 2019; 22: 207-16. |
| [12] | Steutel NF, Zeevenhooven J, Scarpato E, et al. Prevalence of Functional Gastrointestinal Disorders in European Infants and Toddlers. J Pediatr. 2020; 221: 107-14. |
| [13] | Saviano A, Brigida M, Migneco A, et al. Lactobacillus Reuteri DSM 17938 (LimosiLactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin? Medicina. 2021; 57: 643. |
| [14] | Yijing Peng Yizhe Ma Zichen Luo Yifan Jiang Zhimin Xu Renqiang Yu: Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms: Front. Cell. Infect. Microbiol., 18 August 2023 Sec. Intestinal Microbiome: Volume 13 – 2023. |
| [15] | Pärtty A, Rautava S, Kalliomäki M. Probiotics on pediatric functional gastrointestinal disorders. Nutrients. 2018; 10: 1836. |
| [16] | Orel Rok. Effectiveness of Lactobacillus reuteri for prevention and treatment of functional gastrointestinal disorders in infants, children and adolescents (Review). Zdravniski Vestnik. 2018; 82. I83-93. |
| [17] | Klem, F.; Wadhwa, A.; Prokop, L. J.; Sundt, W. J.; Farrugia, G.; Camilleri, M.; Singh, S.; Grover, M. Prevalence, risk factors, and outcome of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology 2017, 152, 1042–1052. |
| [18] | Maxwell, P. R.; Rink, E.; Kumar, D.; Mendall, M. A. Antibiotics increase functional abdominal symptoms. Am. J. Gastroenterol. 2002, 97, 104–108. |
| [19] | Lembo, A.; Pimentel, M.; Rao, S. S.; Schoenfeld, P.; Cash Weinstock, L. B.; Paterson, C.; Bortey, E.; Forbes, W. P. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastoenterology 2016, 151, 1113–1121. |
| [20] | Collins, B. S.; Lin, H. C. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 382–386. |
| [21] | Rajilic-Stojanovic, M.; Jonkers, D. M.; Salonen, A.; Inte Hanevik, K.; Raes, J.; Jalanka, J.; de Vos, W. M.; Manichanh, C.; Golic, N.; Enck, P.; et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? Am. J. Gastroenterol. 2015, 110, 278–287. |
| [22] | Romano, C.; Ferrau, V.; Cavataio, F.; Iacono, G.; Spina, M.; Lionetti, E.; Comisi, F.; Famiani, A.; Comito, D. Lactobacillus reuteri in children with functional abdominal pain (FAP). J. Paediatr. Child Health 2014, 50, 68–70. |
| [23] | Eftekhari, K.; Vahedi, Z.; Kamali Aghdam, M.; Noemi Diaz, D. A randomized double-blind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran. J. Pediatr. 2015, 25, e2616. |
| [24] | Weizman, Z.; Abu-Abed, J.; Binsztok, M. Lactobacillus reuteri 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind placebo-controlled trial. J. Pediatr. 2016, 174, 160–164. |
| [25] | Jadresin, O.; Hojsak, I.; Misak, Z.; Kekez, A. J.; Trbojevi´c, T.; Ivkovi´c, L.; Kolaˇcek, S. Lactobacillus reuteri 17938 in the treatment of functional abdominal pain in children: RCT study. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 925–929. |
| [26] | Maragkoudaki, M.; Chouliaras, G.; Orel, R.; Horvath, A.; Szajewska, H.; Papadopoulou, A. Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr. 2017, 106, 1857–1862. |
| [27] | Coccorullo, P.; Strisciuglio, C.; Martinelli, M.; Miele, E.; Greco, L.; Staiano, A. Lactobacillus reuteri (17938) in infants with functional chronic constipation: A double-blind, randomized, placebo-controlled study. J. Pediatr. 2010, 157, 598–602. |
| [28] | Guerra, P. V. P.; Lima, L. N.; Souza, T. C.; Mazochi, V.; Penna, F. J.; Silva, A. M.; Nicoli, J. R.; Guimarães, E. V. Periatric functional constipation treatment with Bifidobacterium-containing yogurt: A crossover, double-blind, controlled trial. World J. Gastroenterol. 2011, 17, 3916–3921. |
| [29] | Tabbers, M. M.; Chmielewska, A.; Roseboom, M. G.; Crastes, N.; Perrin, C.; Reitsma, J. B.; Norbruis, O.; Szajewska, H.; Benninga, M. A. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: A randomized, double-blind, controlled trial. Pediatrics 2011, 127, 1392–1399. |
| [30] | Dryl, R.; Szajewska, H. Probiotics for management of infantile colic: A systematic review of randomized controlled trials. Arch. Med. Sci. 2018, 14, 1137–1143. |
| [31] | Savino, F.; Cordisco, L.; Tarasco, V.; Palumeri, E.; Calabrese, R.; Oggero, R.; Roos, S.; Matteuzzi, D. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics 2010, 126, 526–533. |
| [32] | Szajewska, H.; Gyrczuk, E.; Horvath, A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A randomized, double-blind, placebo-controlled trial. J. Pediatr. 2013, 162, 257–262. |
| [33] | Sung, V.; Hiscock, H.; Tang, M. L.; Mensah, F. K.; Nation, M. L.; Satzke, C.; Heine, R. G.; Stock, A.; Barr, R. G.; Wake, M. Treating infant colic with the probiotic Lactobacillus reuteri: Double blind, placebo controlled randomised trial. BMJ 2014, 348, g2107. |
| [34] | Chau, K.; Lau, E.; Greenberg, S.; Jacobson, S.; Yazdani-Brojeni, P.; Verma, N.; Koren, G. Probiotics for infantile colic: A randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J. Pediatr. 2015, 166, 74–78. |
| [35] | Mi, G. L.; Zhao, L.; Qiao, D. D.; Kang, W. Q.; Tang, M. Q.; Xu, J. K. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: A prospective single blind randomized trial. Antonie Van Leeuwenhoek 2015, 107, 1547–1553. |
| [36] | Sung, V.; D’Amico, F.; Cabana, M. D.; Chau, K.; Koren, G.; Savino, F.; Szajewska, H.; Deshpande, G.; Dupont, C.; Indrio, F.; et al. Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics 2018, 141. |
| [37] | Savino, F.; Garro, M.; Montanari, P.; Galliano, I.; Bergallo, M. Crying Time and RORγ/FOXP3 Expression in Lactobacillus reuteri DSM17938-Treated Infants with Colic: A Randomized Trial. J. Pediatr. 2018, 192, 171–177. |
| [38] | Fatheree, N. Y.; Liu, Y.; Taylor, C. M.; Hoang, T. K.; Cai, C.; Rahbar, M. H.; Hessabi, M.; Ferris, M.; McMurtry, V.; Wong, C.; et al. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J. Pediatr. 2017, 191, 170–178. |
| [39] | Pärtty, A.; Lehtonen, L.; Kalliomäki, M.; Salminen, S.; Isolauri, E. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: A randomized, controlled trial. Pediatr. Res. 2015, 78, 470–475. |
| [40] | Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Applied Environ Micro. 2004; 70: 1176–81. |
| [41] | Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019; 1125: 121-137. |
| [42] | Daelemans S, Peeters L, Hauser B, et al. Recent advances in understanding and managing infantile colic. F1000Res. 2018; 7: 1426. |
| [43] | Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study. Aliment Pharmacol Ther. 2012; 36: 363-9. |
| [44] | Papagaroufalis K, Fotiou A, Egli D, et al. A Randomized Double Blind Controlled Safety Trial Evaluating d-Lactic Acid Production in Healthy Infants Fed a Lactobacillus reuteri-containing Formula. Nutr Metab Insights. 2014; 22: 19-27. |
| [45] | Depoorter L, Vandenplas Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients. 2021; 24; 13: 2176. |
APA Style
Uddin, M. B., Uddin, S., Deb, B., Hussain, T., Rafi, S. A., et al. (2024). The Role of Lactobacillus Reuteri Probiotic for Preventing Functional Gastrointestinal Disorders in Toddlerhood. International Journal of Gastroenterology, 8(1), 14-21. https://doi.org/10.11648/j.ijg.20240801.14
ACS Style
Uddin, M. B.; Uddin, S.; Deb, B.; Hussain, T.; Rafi, S. A., et al. The Role of Lactobacillus Reuteri Probiotic for Preventing Functional Gastrointestinal Disorders in Toddlerhood. Int. J. Gastroenterol. 2024, 8(1), 14-21. doi: 10.11648/j.ijg.20240801.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijg.20240801.14,
author = {Mohammad Basir Uddin and Shahab Uddin and Bishwajit Deb and Tania Hussain and Sohel Al Rafi and Azizul Islam},
title = {The Role of Lactobacillus Reuteri Probiotic for Preventing Functional Gastrointestinal Disorders in Toddlerhood
},
journal = {International Journal of Gastroenterology},
volume = {8},
number = {1},
pages = {14-21},
doi = {10.11648/j.ijg.20240801.14},
url = {https://doi.org/10.11648/j.ijg.20240801.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijg.20240801.14},
abstract = {Probiotic Lactobacillus reuteri has been shown to be useful for a number of gastrointestinal disorders. Its ability to secrete antimicrobial compounds, prevent pathogenic microorganisms from colonizing the host, and alter the composition of the commensal microbiota in the host are all major contributors to its therapeutic advantages. Not only that, but L. reuteri treatment strengthens the host's defenses against infection and pro-inflammatory cytokine production while enhancing the growth and functionality of regulatory T cells. Numerous pediatric illnesses, particularly those pertaining to the intestinal health of infants, have been found to be well managed by L. reuteri, according to systematic reviews and meta-analyses. According to current research on L. reuteri, it may be useful in the management and avoidance of a number of common clinical disorders, including functional constipation, infantile colic, regurgitation, and diarrhea. Probiotic treatment for pediatric illnesses has had favorable benefits on bowel regularity in individuals with chronic constipation and has been found to successfully reduce screaming and/or fussing time in newborns with colic. Additionally, it quickens the emptying of the stomach and lessens distension. Several research have even come to the conclusion that this probiotic strain reduces the frequency of regurgitation. The potential of this probiotic strain for application in the treatment of several gastrointestinal disorders is evident from all of these findings. Therefore, this study aims to encapsulate and condense the advantages of this probiotic strain in clinical settings, with a particular emphasis on how it supports babies' and toddlers' immune systems and gut health.
},
year = {2024}
}
TY - JOUR T1 - The Role of Lactobacillus Reuteri Probiotic for Preventing Functional Gastrointestinal Disorders in Toddlerhood AU - Mohammad Basir Uddin AU - Shahab Uddin AU - Bishwajit Deb AU - Tania Hussain AU - Sohel Al Rafi AU - Azizul Islam Y1 - 2024/04/11 PY - 2024 N1 - https://doi.org/10.11648/j.ijg.20240801.14 DO - 10.11648/j.ijg.20240801.14 T2 - International Journal of Gastroenterology JF - International Journal of Gastroenterology JO - International Journal of Gastroenterology SP - 14 EP - 21 PB - Science Publishing Group SN - 2640-169X UR - https://doi.org/10.11648/j.ijg.20240801.14 AB - Probiotic Lactobacillus reuteri has been shown to be useful for a number of gastrointestinal disorders. Its ability to secrete antimicrobial compounds, prevent pathogenic microorganisms from colonizing the host, and alter the composition of the commensal microbiota in the host are all major contributors to its therapeutic advantages. Not only that, but L. reuteri treatment strengthens the host's defenses against infection and pro-inflammatory cytokine production while enhancing the growth and functionality of regulatory T cells. Numerous pediatric illnesses, particularly those pertaining to the intestinal health of infants, have been found to be well managed by L. reuteri, according to systematic reviews and meta-analyses. According to current research on L. reuteri, it may be useful in the management and avoidance of a number of common clinical disorders, including functional constipation, infantile colic, regurgitation, and diarrhea. Probiotic treatment for pediatric illnesses has had favorable benefits on bowel regularity in individuals with chronic constipation and has been found to successfully reduce screaming and/or fussing time in newborns with colic. Additionally, it quickens the emptying of the stomach and lessens distension. Several research have even come to the conclusion that this probiotic strain reduces the frequency of regurgitation. The potential of this probiotic strain for application in the treatment of several gastrointestinal disorders is evident from all of these findings. Therefore, this study aims to encapsulate and condense the advantages of this probiotic strain in clinical settings, with a particular emphasis on how it supports babies' and toddlers' immune systems and gut health. VL - 8 IS - 1 ER -
Department of Paediatric, North East Medical College Hospital, Sylhet, Bangladesh
Department of Paediatric, Sylhet Women's Medical College and Hospital, Sylhet, Bangladesh
Department of Paediatric, Sreemongal Upazila Health Complex, Sylhet, Bangladesh
Department of Paediatric, North East Medical College Hospital, Sylhet, Bangladesh
Department of Paediatric, Sylhet MAG Osmani Medical College Hospital, Sylhet, Bangladesh
Department of Paediatric, 250 Bed Sadar Hospital, Sylhet, Bangladesh
